Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01365702|
Recruitment Status : Unknown
Verified June 2011 by Seoul National University Bundang Hospital.
Recruitment status was: Recruiting
First Posted : June 3, 2011
Last Update Posted : June 7, 2011
|Condition or disease|
|Lung Disease, Obstructive Tuberculosis|
Tuberculosis can cause lung parenchymal destruction, volume loss, secondary bronchiectasis. Patients with TB destroyed lung complain chronic respiratory symptoms, such as chronic cough, sputum, dyspnea, exercise intolerance, and acute exacerbations. Some of them have chronic airflow obstructions on pulmonary function tests, similar to those of smokers.
Previous large randomized controlled trials, targeting patients with smoking related moderate to severe COPD,demonstrated that tiotropium improved quality of life and respiratory symptom with tolerable long-term safety. The investigators want to evaluate whether tiotropium can improve chronic respiratory symptom,an lung function in patients with COPD due to TB destroyed lung.
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Clinical Efficacy of Tiotripium in Patients With Airflow Obstruction Due to TB Destroyed Lung|
|Study Start Date :||June 2011|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2012|
|Tiotropium in TB destroyed lung|
- St-George respiratory questionnaire(SGRQ) [ Time Frame: 6 months after initiation of tiotropium once-daily inhalation ]
- lung function [ Time Frame: 6mo after initiation of tiotropium once-daily inhalation ]
- cough VAS [ Time Frame: 6mo after initiation of tiotropium once-daily inhalation ]
- adverse reaction of tiotropium [ Time Frame: 6 months after initiation of tiotropium once-daily inhalation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01365702
|Korea, Republic of|
|Seoul National University Bundang Hospital||Recruiting|
|Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707|
|Contact: Sei Won Lee, M.D. 82-31-787-7053 firstname.lastname@example.org|
|Principal Investigator:||Sei Won Lee, M.D.||Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical research center, Seoul National University Bundang Hospital|